Gossamer Bio Plunges 80% in a Day... Falls Short of Trial Bar with Just 13m Gain [New York Movers]
Shares of Gossamer Bio (ticker: GOSS) have plunged by more than 80%. The drop came after news that the company’s investigational pulmonary arterial hypertension (PAH) treatment failed to meet the threshold for statistical significance in a clinical trial.
Gossamer Bio closed on the 23rd (local time) at 0.42 dollars, down 80.13% from the previous trading day. In after-hours trading, the stock is falling nearly an additional 2%.
According to Reuters, the company’s PAH therapy seralutinib improved the 6-minute walking distance (6-minute walking distance) by only 13.3 meters compared with placebo at week 24 of the trial. This fell short of the threshold for statistical significance set in the study.
The company said that while it reviews certain discrepancies related to the placebo response observed in the PAH trial, it also plans to temporarily halt patient enrollment in a separate late-stage clinical trial that was underway for another lung disease.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Faheem Hasnain, Chief Executive Officer (CEO) of Gossamer Bio, said on a conference call with analysts that when the latest late-stage clinical data are combined with earlier mid-stage trial data, they form a "compelling package" to submit to the U.S. Food and Drug Administration (FDA). He argued that the results should be viewed as "clinically meaningful."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.